Phytochemical, anti-hyperalgesic and anti-inflammatory potential of miconia albicans sw. triana (melastomataceae) and health benefits of miconia genus

Abstract

This study reviews existing research on the therapeutic potential and molecular mechanisms of the Miconia genus, a group of medicinal plants with 282 species in Brazil and other tropical American nations. The research focuses on the pharmacological properties of phytochemicals in the Miconia genus and their impact on well-being, while addressing safety considerations. The study conducted literature searches across electronic databases and identified 14 species from the genus Miconia, with the most frequently used species being Miconia albicans Sw. Triana and Miconia rubiginosa (Bonpl.) DC. M. albicans showed significant efficacy and potential for developing safe drugs to treat pain and inflammation. Another study aimed to identify the anti-arthritic and anti-inflammatory profile of M. albicans ethanolic leaf extract (EEMA), which was found to have 23 compounds. The EEMA significantly decreased tumour necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β) levels in pleural lavage, lowered mechanical hyperalgesia, nociceptive and hyperalgesic behaviors, and enhanced mobility. In the open-field test, EEMA significantly improved grip strength and decreased the dimension of complete Freund's adjuvant (CFA)-induced ipsilateral knee edema. In conclusion, the Miconia genus's rich history in folk medicine, diverse therapeutic potential, and associated molecular mechanisms highlight its promise as a source for safe and effective treatments for pain and inflammation.